A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration
Sponsor: Amgen
A PHASE3 clinical study on Neovascular (Wet) Age-related Macular Degeneration (AMD), this trial is completed. The trial is conducted by Amgen and has accumulated 32 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
32 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 27 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Feb 2024 [monthly]
Completed PHASE3
-
Jun 2023 — Oct 2023 [monthly]
Completed PHASE3
-
Mar 2023 — Jun 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Parexel
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, Hong Kong , Abilene, United States , Akita, Japan , Asahikawa, Japan , Augusta, United States , Baltimore, United States , Beersheba, Israel , Belgrade, Serbia , Bellaire, United States , Berlin, Germany and 90 more locations